Blueprint Medicines (BPMC) Tops Q3 EPS by 18c

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($2.20), $0.18 better than the analyst estimate of ($2.38). Revenue for the quarter came in at $56.56 million versus the consensus estimate of $50.66 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Carnival shares drop despite earnings beat on weak guidance